Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
BioLexa is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized, communities consisting of bacteria adhered to a surface (both biological and abiotic surfaces) and to other bacteria, and often with a protective extracellular matrix. Mature bacterial biofilms often result in chronic, recurrent infections that are difficult to treat due to the barrier effect of the biofilm that facilitates antibiotic resistance and avoiding immune system mechanisms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping the bacteria in a more susceptible state to antimicrobial therapy. This novel mechanism of action has the potential to broadly treat clinical manifestations resulting from Staphylococcal biofilm formation.
BioLexa topical agent is under development for the following indications:
The BioLexa Phase 1b/2a study in patients with atopic dermatitis was initiated in Q1 2021.
An interim data readout from the clinical study is expected in late Q2/early Q3 followed by enrollment for Cohort 2.